Yes, a generic version of gemtesa is available. The U.S. Food and Drug Administration (FDA) has approved generic versions of vibegron, the active ingredient in gemtesa [1].
When did the generic version become available?
The first generic versions of vibegron were approved by the FDA in late 2023 [1].
Who manufactures the generic gemtesa?
Several pharmaceutical companies have received FDA approval to market generic versions of vibegron. These include Aurobindo Pharma, Taro Pharmaceuticals, and Teva Pharmaceuticals [1].
What is gemtesa used for?
Gemtesa is a medication used to treat overactive bladder (OOB) with or without urinary incontinence, urinary urgency, and urinary frequency in adults [2].
How does generic vibegron work?
Vibegron is a beta-3 adrenergic agonist. It works by relaxing the bladder muscle, which helps to increase bladder capacity and reduce the symptoms of overactive bladder [2].
Are there other treatments for overactive bladder?
Other treatments for overactive bladder include behavioral therapies, other medications such as anticholinergics, and procedures like Botox injections or nerve stimulation [3].
What are the potential side effects of vibegron?
Common side effects of vibegron include headache, nasopharyngitis (common cold symptoms), diarrhea, nausea, and upper respiratory tract infection [2].
When does the patent for gemtesa expire?
The patent exclusivity for gemtesa is complex, with multiple patents covering the drug. While initial patent expirations could allow for generic entry, challenges and further patent filings can affect the timeline [4]. For detailed patent expiration information, DrugPatentWatch.com is a resource [4].